medicine-news-1/cryolife-reports-record-quarterly-revenues-of--2428-2-million-53206-10/;msg18067;topicseen
| We're sorry, that page (http://www.bio-medicine.org/medicine-news-1/cryolife-reports-record-quarterly-revenues-of--2428-2-million-53206-10/;msg18067;topicseen) was not found. Search medicine news 1 cryolife reports record quarterly revenues of 2428 2 million 53206 10 ;msg18067;topicseen at Google Search medicine news 1 cryolife reports record quarterly revenues of 2428 2 million 53206 10 ;msg18067;topicseen at Yahoo Search medicine news 1 cryolife reports record quarterly revenues of 2428 2 million 53206 10 ;msg18067;topicseen at Msn |
Breaking Biology Technology:Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2Microban Signs Exclusive Agreement with Sharp Electronics to Launch Calculators with New Microban(R) 3G Silver(TM) Antimicrobial Technology 2Successful Stem Cell Therapy for Treatment of Eye Disease 2Successful Stem Cell Therapy for Treatment of Eye Disease 3Successful Stem Cell Therapy for Treatment of Eye Disease 4Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3
[0] Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer[0] Microban Signs Exclusive Agreement with Sharp Electronics to Launch Calculators with New Microban(R) 3G Silver(TM) Antimicrobial Technology[0] Successful Stem Cell Therapy for Treatment of Eye Disease[0] Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products
Breaking Medicine Technology:Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6JumpStart Invests in Checkpoint Surgical 6118 1JumpStart Invests in Checkpoint Surgical 6118 2JumpStart Invests in Checkpoint Surgical 6118 3Some chest pain patients wait longer than 10 minutes to see ER physician 61033 1Some chest pain patients wait longer than 10 minutes to see ER physician 61033 2Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 6115 1Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 6115 2
[0] Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer[0] Boston Scientific Announces Pricing of $2 Billion of Senior Notes[0] Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer
| Copyright © 2003-2007 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |